- Part 15: For the preceding part double click ID:nRSH4027Rn
infringement. In the US, they may also seek enhanced (ie up to treble)
damages for alleged wilful infringement of their patents.Details of
material patent litigation matters can be found in Note 27 to the
Financial Statements from page 186.
Price controls and reductions Impact
Most of our key markets have experienced the implementation of various Due to these pricing pressures, there can be no certainty that we will be able to charge prices for a product that, in a particular country or in the aggregate, enable us to earn an adequate return on our product investment. These pressures, including the increasingly restrictive reimbursement policies to which we are subject, as well as potential legislation that expands the commercial importation of medicines into the US, could materially adversely affect our business or results of operations.We expect these pricing pressures will continue, and may increase. ImpactWhile new patients entering the US healthcare system due to the ACA may lead to a slight increase in prescription drug utilisation, we expect that our financial and other costs resulting from the ACA, many of which we are unable to accurately estimate, will far outweigh any increase in Product Sales.The continued disparities in EU and US pricing systems could lead to marked price differentials between markets, which, by way of the implementation of existing or new reference pricing mechanisms, increases the pricing pressure affecting the industry. The importation of pharmaceutical products from countries where prices are low due to government price controls, or other market dynamics, to countries where prices for those products are higher, is already prevalent and may increase. Increased transparency of net prices and strengthened collaboration by governments may accelerate the development of further cost containment policies (such as procurement or the comparison of net prices etc).
cost control or reimbursement mechanisms for pharmaceutical products.For
example, in the US, prices are being depressed through restrictive
reimbursement policies and cost control tools such as restricted lists
and formularies, which employ 'generic first' strategies and/or require
physicians to obtain prior approval for the use of a branded medicine
where a generic alternative exists. These mechanisms can be used by
- More to follow, for following part double click ID:nRSH4027Rp